ONCrg Sentinel – Oncology Resource Group

Proficient + Discerning = Best-In-Class

ONCrg experts are highly proficient in conducting oncology market surveillance. We are adept at discerning how new scientific, clinical and market events impact each treatment landscape and keep Biopharma, CROs and Cancer Research Center clients on the cutting-edge of change by confidently preparing them for what’s next.

Our analysts vigilantly monitor multiple secondary and primary sources to comprehensively cover clinical trials, product developments, company activities, and regulatory news to deliver monthly reports with unparalleled CI value.

ONCrg Sentinel™TrialsProductsCompaniesRegulatory

ONCrg Sentinel:

ONCrg specialists vigilantly monitor scientific, clinical and commercial developments via multiple secondary and primary sources to provide expert CI support year-round with succinct but comprehensive analyses of market changes and new data releases.

Trials:

Our comprehensive coverage of clinical trials include a brief write up about estimated completion date changes, significant enrollment changes, and clinical trials on hold or terminated and why. More detailed analysis and insights are provided for new and completed clinical trials Ph II and greater.

Products:

We look for information that is scientifically and clinically relevant to our pipelines (all drugs in Phase II development and beyond), whether it is regulatory news, product news, company news, or clinical trial news.

Companies:

Our analysis of company news includes coverage of research, development and marketing collaborations, alliances, mergers, acquisitions, IPOs and major funding activities, and other major commercial developments in oncology.

Regulatory:

Our analysis of regulatory news includes coverage of FDA approvals, breakthrough therapy designations, Orphan Drug designations, BLA submissions, as well as European Commission, NICE and other major regional activities.

Our best-in-class competitive intelligence coverage serves commercial, medical and scientific teams worldwide.

Solid Tumors
GI - Gastrointestinal	GU - Genitourinary	Breast / Gyn	Lung	Other
Colorectal	Bladder	Breast	NSCLC	Gliomas
Esophageal	Prostate	Endometrial	SCLC	HNSCC
Gastric	RCC	Ovarian		Melanoma
HCC				STS
Pancreatic

Immuno-Oncology	MOAs	Hematologic Malignancies
Emerging IO	ADC	ALL	MDS	MPNs
Late Stage IO	Cell Therapies	AML	MM	NHL
	DDR	CLL

Our best-in-class competitive intelligence coverage serves commercial, medical and scientific teams worldwide.

Solid Tumors

GI - Gastrointestinal

Colorectal Esophageal Gastric HCC Pancreatic

GU - Genitourinary

Bladder Prostate RCC

Breast / Gyn

Breast Endometrial Ovarian

Lung

NSCLC SCLC

Other

Gliomas HNSCC Melanoma STS

Immuno-Oncology

IO Emerging IO Late Stage

MOAs

ADC Cell Therapies DDR

Hematologic Malignancies

ALL AML CLL MDS MM MPNs NHL

ALREADY A CLIENT? CLICK HERE TO REGISTER.

Why We Make a Difference

Oncology Coverage

“BRAVO!! Most comprehensive map that I have reviewed for current SOC; and then every MoA and compound in development. Very Impressive. My hat is tipped to your team. I will distribute it across to my team and School is in Session.”

“These reports are incredibly informative and helpful as we think about our research strategy and drug developments options in these indications. I greatly appreciate you and the ONCrg team’s efforts to generate these reports and summaries.

“I love the tumor specific reports that give me a lay of the land, are easily digestible. I really appreciate the implications and commentary in each report.”

“I am quite impressed with the approach that you have taken to developing market assessments based on clinical trials reporting in a variety of settings. I appreciate the access to the meeting trials compendia in my core areas of interest”

“I find the depth of information and their very succinct explanations to be extremely well written and easy to read, so this would enable me to stay aware of compounds moving up the ladder. Great work”

“Receiving the quarterly Emerging IO ONCrg pipeline reports was like Christmas morning for me, as it was my job was to be on top of the landscape in that space. The quality and completeness of those reports are incredible.”

“I really like your reports, I find them very readable, even when covering tumors that I’m not intimately familiar with.”

“Thank you so much and thank you for taking an extra 20 minutes. That was really great. So really appreciate your time. And I think I speak for the entire team that say we really appreciate the report. So. So thank you again for that. It’s really valuable in our work.”

“Just one comment before we start that I love these reports. They’re really, really helpful. So well done to to Lisa for putting these together because every time it’s super helpful for us.”

How Did You Hear About Us

Why We Make a Difference

Oncology Coverage

Footer

How Did You Hear About Us